NEW research has shown that pridopidine, a sigma-1 receptor agonist, does not exhibit a significant impact on the progression of amyotrophic lateral sclerosis (ALS) over a 24-week period.

It marked their first true test against an elite playoff contender since acquiring Luka Doncic earlier this month, and they responded with a convincing 123-100 victory. The primetime Western ...